On December 2014 the European Medicines Agency (EMA) and the U.S.A. Food and Drug Administration (FDA) approved the PARPi olaparib [13-15] for treatment of BRCA1/BRCA2 mutated ovarian cancer. Here, BRCA1 is linked to ovarian carcinoma.